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Tuberculosis remains a major health threat throughout the world, despite having a vaccine and 
treatments. Mycobacterium tuberculosis (Mtb) infects alveolar macrophages in the lung and 
inflammation occurs after infection. The lung microbiome in regards to Mtb infection is poorly 
understood, and whether inflammation from infection affects the lung microbiome is unknown. 
The goal of our study is to determine whether Mtb induces a significant and durable change in 
the lung microbiome of cynomolgus macaques. We investigated and compared the community 
clusters between the lung and oral cavity, assessed how the diversity of the lung microbiota 
changes throughout infection, and associated these changes in the lung with inflammation. 
Bronchoalveolar lavage (BAL) was obtained pre-infection and at several time points post-Mtb 
infection, as well as oral wash and saline bronchoscope control samples from respective 
macaques. Operational taxonomic units (OTUs) were generated after 16s rRNA sequencing was 
performed once DNA was extracted from collected samples.  We profiled microbial 
communities to see the community structure differences between oral and lung environment and 
show how the microbiome changes throughout infection. PET/CT imaging was used to visualize 
and quantify inflammation over the course of infection by using FDG avidity (total PET HOT). 
Our results show that the oral and lung compartments are distinct with regard to community 
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v 
structure, distinct bacterial taxa are more relatively abundant in certain lobes, and lung 
inflammation and lung microbiome changes are variable within macaques and between 
macaques. Analysis of the first cohort of macaques (N=10) did not reveal correlations between 
lung inflammation and relative abundance or alpha-diversity, but our data is preliminary and 
based on small sample size. Our sample size will greatly increase after the second cohort of 
macaques are fully sequenced and analyzed. These changes and disruptions in the lung 
microbiome may have public health relevance in regards to overall lung health and may also play 
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1.0  INTRODUCTION 
Tuberculosis remains a health treat throughout the entire world, despite having a vaccine and 
treatments. Development of nonhuman primate models that mimic many aspects of infection in 
humans helps researchers study the course of infection of Mycobacterium tuberculosis (Mtb), as 
well as the pathogenesis, immune response, and host interactions during disease. Nonhuman 
primate models are also useful when studying the lung microbiome, an understudied field due to 
many obstacles regarding invalid beliefs of the lung, sample collection, and respiratory tract 
kinetics. The research in this thesis focuses on investigating the changes that the lung 
microbiome undergoes after Mtb infection. A longitudinal study of the lung microbiome and 
tuberculosis has never been performed before, and investigating how the lung microbiome 
changes after and throughout Mtb infection may give us insight about important aspects of 
infection and lung health. 
1.1 TUBERCULOSIS 
1.1.1 Epidemiology and Clinical Definitions 
Tuberculosis (TB) remains a major health threat throughout the world. In 2015, there were 10.4 
million new cases of TB, and 1.8 million people died from the disease1. TB mainly affects people 
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in low and middle-income countries. For example, the incidence of TB is >250-fold higher in 
South Africa than in the United States2. Of all worldwide TB cases, 60% occur in six countries: 
China, India, Indonesia, Nigeria, Pakistan, and South Africa1. Many areas that are affected by 
TB, such as Sub-Saharan Africa, are also afflicted by the HIV epidemic, resulting in even higher 
risk for development for active (symptomatic and transmissible) TB3. Although a vaccine and 
treatments exist for TB, vaccination yields partial protection (efficacies range from 0-80%)4 and 
drug treatments are lengthy and intensive3. Lack of access to healthcare, rise of multi-drug 
resistant TB, HIV status, and other societal, environmental, and economical risk factors are also 
responsible for the high global burden of TB. 
Robert Koch discovered the etiologic agent that causes TB, Mycobacterium tuberculosis 
(Mtb), in 18825. Mtb infects via the lungs, but dissemination is possible. When an individual 
becomes infected with Mtb, 90-95% of people remain asymptomatic, which is termed latent TB 
infection (LTBI)6. The other 5-10% of people will develop active disease. Although one-third of 
the world’s population is latently infected with Mtb, only 5-10% of these people will experience 
reactivation and develop active TB in their lifetimes6.  In clinical terms, LTBI is asymptomatic 
and non-transmissible. In contrast to LTBI, active TB infection is transmissible via aerosolized 
droplets, and people with active disease experience a range of symptoms such as fever, fatigue, 
appetite loss, weight loss, and chronic cough2. Individuals who have LTBI or active disease will 
have a reaction to the tuberculin skin test (TST), which contains mycobacterial antigens, 
demonstrating an immune response to the bacteria. A non-infected person would not react to 
TST since their immune response has never seen these antigens before, therefore an immune 
response will not be elicited. During LTBI or active disease, IFN-gamma release assays (IGRA), 
which measure reactivity to Mtb-specific antigens, will also be positive2.  
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1.1.2 The Spectrum of M. Tuberculosis Infection 
It is now appreciated that strictly using ‘latent’ and ‘active’ to describe the disease status of an 
infected individual is not ideal. This is because disease status entails much diversity and can be 
described as a spectrum of disease, which can range from Mtb clearance to disseminated disease 
(Fig. 1)2,7.  
 
Figure 1. The spectrum of Mtb infection 
After infection, many possible outcomes are possible. These can range from disease clearance (either via the innate 
immune response or the adaptive immune response) to complete Mtb systemic dissemination. 
 
 
On the left-most side of the disease spectrum, one would have Mtb clearance via the 
innate immune response. These individuals do not develop an adaptive immune response to Mtb, 
resulting in negative TST and IGRA results. Bacterial clearance that is accompanied by the 
development of an adaptive immune response to Mtb is also possible; these individuals would 
have positive responses to immunological tests for TB2. In those who do not clear infection, the 
bacteria persist under strong host immune control (‘true’ LBTI)7. Further down the spectrum, 
there is subclinical infection. These individuals remain asymptomatic but are able to transmit 
Mtb, and may be culture positive, indicating active bacterial replication8. Patients who have 
active pulmonary (in the lungs) disease display symptoms, can transmit Mtb, and immune 
 4 
 
responses and molecular diagnostic testing methods are all positive for bacterial presence. Mtb 
may disseminate, resulting in extra pulmonary TB or even miliary TB/sepsis2,7.  
1.1.3 Transmission and Immunology 
Mtb infection is transmitted via inhalation of droplet nuclei that have been expelled from the 
lungs of an infected person with subclinical or active disease. The bacteria travel down into the 
lower respiratory tract where they reach the lungs. Once in the lungs, the bacteria are engulfed by 
alveolar macrophages via receptor-mediated phagocytosis9. Inflammation occurs post-infection, 
and the infected macrophages then invade the lung parenchyma leading to the recruitment of 
large amounts of immune cells2,7.  
The establishment of the adaptive immune response after Mtb infection occurs at a 
relatively slow rate. A positive tuberculin skin test, showing an adaptive immune response, 
occurs at roughly 6 weeks post-infection for humans and roughly 4-6 weeks post-infection in 
macaques10. The adaptive immune response in regards to TB infection is delayed due to a 
number of immunological hindrances in the process of antigen presentation, MHC class II 
loading, and T cell priming. As Mtb infects the alveolar macrophage, there may be defects in the 
innate inflammatory response and entry of antigen presenting cells, causing delays in APC 
loading, and T cell recruitment, ultimately delaying T cell priming in the mediastinal lymph 
nodes11.  
As Mtb continues to interact with alveolar macrophages and dendritic cells throughout 
infection, several pro-inflammatory cytokines (tumor necrosis factor-α, IL-12, and IL-23) are 
released, along with several chemokines such as CCL2, CCL5, and CXCL812. IL-23 and IL-17 
are also important players in T-cell dependent inflammatory responses during infection, as both 
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IL-17- and IL-23-deficient mice displayed a decrease in antigen-specific inflammatory 
responses13,14. Inflammatory events that occur after Mtb infection are regulated by IFN-y and IL-
2 production by activated T cells that have been recruited to the infection site15. The pro-
inflammatory response helps in granuloma formation and bacterial burden reduction, therefore it 
is crucial for infection control12. There are also a number of anti-inflammatory factors involved 
in the host response to TB such as Tregs, and the release of IL-10, IDO, and PD-1 that may be 
associated with both host control and bacterial persistence and evasion16,17,18,19. 
1.1.4 The Granuloma 
As large amounts of immune cells are recruited due to chemokines released, a granuloma starts 
to form. The granuloma is the hallmark of TB. The granuloma is a highly organized structure 
composed of many different types of immune cells such as macrophages, monocytes, 
neutrophils, epithelioid cells, and multi-nucleated giant cells surrounded by an area of 
lymphocytes20. Figure 2 shows a cartoon diagram of the structure and organization of cell types 
located in a granuloma found in the lungs of an infected individual. Individual granulomas can 
differ in both structure and organization. The function of the granuloma has two main, yet 
contradictory, functions that both benefit the host and bacteria. The granuloma is the site of both 
host control of Mtb and Mtb persistence 21. The accumulation of immune cells at the site of 
infection function to contain Mtb replication and prevent dissemination. However, Mtb can live 




Figure 2. Structure and organization in a TB granuloma 
A necrotic center is surrounded by a macrophage rich region, ultimately surrounded by a ‘lymphocyte cuff’ rich in T 
and B cells. 
1.1.5 The Use of PET/CT Imaging to Track Granulomas 
A valuable tool to track granulomas and inflammation over time is positron emission 
tomography (PET) fused with computed tomography (CT), using 2-deoxy-2-[18F]-d-
deoxyglucose (FDG) as a probe. FDG is taken up and retained by metabolically active cells, such 
as the cells of the TB granuloma. It has been shown that FDG avidity is increased when murine 
lymphocytes are activated by Con A22, indicating that FDG uptake is increased during 
inflammation. Therefore, FDG avidity can be used as a general, nonspecific marker of 
inflammation. FDG avidity is normalized in order to give us a quantifiably measurable amount 
of inflammation within the granuloma, called total PET HOT.   
PET/CT imaging has been extremely useful in studying TB infection and disease in 
macaques by allowing us to track granulomas and total inflammation over the course of 
infection. Coleman et. al (2014) has  shown that by using early PET/CT scans, it is possible to 
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predict the outcome of TB disease24. Treatment efficacy can also be assessed using this 
method25, simplifying processes that would otherwise be relatively more difficult to perform. By 
using serial PET/CT imaging techniques over the course of Mtb infection, granulomas and 
inflammation can be visualized over time. This imaging method, when used with the NHP 
model, allows us to study a wide range of questions regarding TB, such as inflammatory 
responses and infection dynamics, treatment efficacy, and disease outcomes. 
Using [18F] FDG PET/CT imaging, Lin et. al (2014) has shown that granulomas are both 
dynamic and independent, even within the same individual23. A granuloma in one area of a lung 
lobe of a macaque can slowly regress over time (Fig. 3) to the point where it may be difficult to 
even detect using PET/CT. In contrast, in another area of a lung lobe of the same macaque, 
granulomas can progress over time. Multiple granulomas can progress to such extremes that they 
can consolidate into one large granuloma.  
 
Figure 3. Hypothetical PET/CT image showing granuloma dynamism throughout time 
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In granuloma group A, granulomas progress through time and ultimately consolidate into one large granuloma. 
Granuloma B progresses until 7 months post-infection, but starts to regress by 10 months post-infection. Granuloma 
C regresses throughout infection. Regression occurs post-treatment; granuloma C cannot be detected on PET/CT 
post-treatment. (Information obtained from Lin, 201423) 
 
Granulomas also display a large range of structural heterogeneity, differing in cell 
composition and distribution. The necrotic granuloma is commonly found in active disease, and 
is composed of a non-cellular caseous center, epithelioid macrophage-rich middle region, 
ultimately surrounded by a well-defined ‘lymphocyte cuff’ of T and B cells26. Suppurative 
granulomas also have a well-defined lymphocyte cuff, an epithelioid macrophage-rich middle 
region, but contain centers that have high amounts of neutrophils. A fibrotic granuloma, 
commonly found in clinically latent TB, contains mineralized material surrounded by regions of 
fibrotic tissue26. Fibrotic granulomas usually have small numbers of lymphocytes and 
macrophages, and are considered a ‘successful outcome’. When the host controls the Mtb, 
necrosis no longer occurs and the caseum is eventually replaced with this calcified and fibrotic 
material27. There are also non-necrotic granulomas, containing dense macrophage areas, random 
neutrophil distribution, and no caseous/necrotic material26. Ultimately, the unique dynamism and 
structural heterogeneity of each granuloma results in an immunological response that is quite 
variable from granuloma to granuloma and individual to individual. 
Overall, TB displays a spectrum of outcomes over time. The infection is highly 
associated with a pro-inflammatory response, resulting in the hallmark of Mtb infection – the 
granuloma. Granulomas display large amounts of heterogeneity, and are independent and 
dynamic within individuals. The granuloma functions to immunologically contain the Mtb, and 
the Mtb can persist and survive within this structure. If a granuloma is unable to control 
infection, pathologies such as granuloma consolidation, cavity formation, TB pneumonia, or 




1.2 THE LUNG MICROBIOME 
The microbiome can be defined as the microbiota, or microbes in a population, found in a 
specific place at a specific time28. Many studies have been performed investigating the effect of 
TB on the gut microbiome. One study has found that alteration of the gut microbiota results in 
immune control failure of TB infection –colonization with H. hepaticus resulted in a imbalance 
of Mtb-immune system crosstalk, resulting in lack of Mtb growth control, inflammation 
outbreaks, and increased lung pathology.29 Another study found that altering the gut microbiota 
results in an increased susceptibility to TB30, and it has been shown that Mtb infection results in a 
loss of diversity within the gut microbiota, possibly due to immune signaling between the lung 
and the gut31. However, regardless of TB being a respiratory disease, the lung microbiome with 
respect to Mtb infection remains poorly studied. This is due to many obstacles regarding defining 
the lung microbiome, sample collection, and general knowledge regarding the lung environment. 
1.2.1 Obstacles in Studying the Lung Microbiome 
One of the first obstacles that arose in the lung microbiome field was the long-standing belief 
that the normal lung was completely sterile. Although this claim was quite remarkable – a warm, 
moist mucosal environment that undergoes high airflow with the external environment, located 
just beneath the oropharynx, would be completely sterile – it was so embedded as common 
scientific knowledge that it was usually stated without question32. Many misunderstandings led 
to the origin of this belief. Culture-based methods that supplied poor growth conditions for 
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anaerobes were originally used to identify bacteria present in healthy lungs33. Absence of growth 
was misinterpreted as absence of bacteria in the lungs. This belief halted any preliminary lung 
microbiome research from occurring and was so firmly established that the Human Microbiome 
Project omitted the lung from its list of sampling sites from its first round of the project34. 
However, in the beginning of the 21st century, culture-independent methods such as 16S 
rRNA sequencing became more popular. Applications of culture-independent methods pertaining 
to the lungs were first used in patients with cystic fibrosis35,36, showing a wide range of bacterial 
diversity in sputum samples. The use of bronchoalveolar lavage (BAL) samples allowed 
researchers to sample just the lower airways, showing that healthy airways did contain residential 
bacteria that were distinct from the upper airways, and the bacterial taxa found in healthy lungs 
were distinct from taxa found in diseased lungs32. These findings all invalidated the old belief 
that the healthy lung was sterile. 
Although the statement of lung sterility was refuted, many obstacles remain regarding the 
lung microbiome. There remains a blurred line between the upper and lower respiratory tracts, 
which are diagramed in Figure 4. It is unknown how much the upper respiratory tract (URT) 
microbiome influences the lower respiratory tract (LRT) microbiome although many researchers 
have tried to address this question. One potential solution that has been attempted is to sample 
both the URT and LRT, and subtract the URT from the LRT37. However, a downfall to this 
methodology is that clinically important species that are in the LRT may also be present in the 





Figure 4. The respiratory tract 
The respiratory tract of humans starts at the mouth/nose and then ends in the lungs. The upper respiratory tract 
consists of the nasal cavity, oral cavity, nasopharynx, oropharynx, laryngopharynx, larynx. The lower respiratory 
tract consists of the lungs, bronchi, alveoli. The trachea acts as the bridge between the upper and lower respiratory 
tracts and connects the larynx to the bronchial trees. (Information obtained from Huffnagle, 201638) 
 
Another method that has been used is the application of the neutral theory of community 
ecology39. This theory states that all species in a community (the lung) are functionally 
equivalent, meaning species distribution is not due to environmental selection. Overall, the 
theory describes that microbes that differ significantly between sites (deviation from 
“neutrality”) may be important species in the lung40. 
A second theory, the island model of biogeography, proposed by Dickson et. al, explains 
that the composition of the lung microbiome depends on immigration and elimination factors, as 
well as reproduction rates of the microbial community members41. Microbial immigration into 
 12 
 
the lungs may occur due to microaspiration, bacterial inhalation via the air, or through direct 
mucosal dispersion. Elimination mechanisms may consist of cough, mucociliary clearance, and 
host immune defenses41. Examples of growth conditions that may affect microbial reproduction 
rates include changes in pH, temperature, nutrient availability, inflammatory cell concentration 
and/or activation, and oxygen tension42. However, none of these methods have become widely 
accepted in the field, leaving the overall question of how the URT and LRT influence each other, 
unanswered.  
1.2.2 Contamination Controversies and Issues  
An important difficulty that arises when performing research on the lung microbiome is the 
subject of sample collection. Ideally, one would want to obtain the lung tissue itself and digest 
the entire sample, allowing us to get the best representation of the lung microbiome without 
potential contamination of other microbes from other body sites43 (Fig. 5). However, this is 
rarely feasible due to the highly invasiveness of collection procedures and cannot be used in 
longitudinal studies. For this reason, researchers tend to use either sputum or bronchoalveolar 
lavage (BAL) samples in order to simplify sample collection and accessibility. Sputum samples, 
although completely non-invasive allowing for longitudinal analysis, are always contaminated 
with microbes that are present in the oropharynx and other areas of the upper respiratory 
system44. Sputum sampling may also only sample higher sections of the lower respiratory tract. 
Sputum samples ultimately give a very inaccurate representation of the lung microbiome. 
Bronchoalveolar lavage (BAL) samples, obtained from a washing of the airways via 
bronchoscopy, are collected in a more invasive manner than sputum. However, unlike sputum, 
they give a better representation of the lung microbiome because the bronchoscope does not 
 13 
 
collect from the upper respiratory tract, and mainly samples the lower respiratory tract43. 
Although a risk of potential contamination may still exist from the microbes that come into 
contact with the bronchoscope while it travels through the mouth and upper airways, BAL 
sampling is the ‘happy medium’ of lung microbiome sampling methods.  
 
Figure 5. Potential sites for contamination while sampling the respiratory tract 
Sputum samples may contain contamination from the URT, oral cavity, and nasopharynx. BAL samples may 
contain contamination from the URT if the bronchoscope has residual microbes from these sites. Ideally, one would 
sample the lung tissue itself, which samples only the LRT/lung microbiota with minimal contamination from other 
sites. 
 
In addition to contamination due to sampling method, contamination may occur during 
sampling processing. Salter et. al has shown that bacterial DNA contamination is present in 
commonly used sterile laboratory reagents and also sterile reagents that are used in DNA 
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extraction kits45. The need for negative controls is absolutely crucial because the lung contains 
such a small level of bacteria that any sort of contamination may be significant. Negative 
controls can consist of kit reagent controls, PBS extraction controls, and a bronchoscope wash 
control in order to control for every step of the sample collection and extraction processes. 
1.2.3 Lung Disease, Dysbiosis, and Inflammation  
Past studies have shown that the lung microbiome is important in respiratory diseases such as 
asthma32,46, COPD47,48, cystic fibrosis49, and pneumonia41. According to the island model of 
biogeography proposed by Dickson et al., in a state of lung disease, immigration and elimination 
becomes unbalanced and growth conditions are altered41. Microbial immigration may be 
increased due to gastroesophageal dysfunction50. Elimination may be increased due to cough or 
host inflammatory cell activation. As lung disease progresses, the lung environment shifts, 
changing growth conditions and ultimately altering the reproduction rates of lung microbiota. 
For example, inflammation of the respiratory tract during cystic fibrosis increases mucus 
production, resulting in low-oxygen pockets and increased temperature of the environment of the 
lung51,52. This change in environment may favor the growth of certain bacterial species. Overall, 
lung disease causes changes in immigration and elimination factors as well as changes in growth 
conditions, ultimately changing the composition of the lung microbiome. The microbial 
imbalances caused by lung disease can be described as dysbiosis. 
Microbial dysbiosis that occurs from lung disease not only is caused by inflammation, but 
can also cause inflammation. This results in a positive feedback dysbiosis-inflammation loop41, 
shown in Figure 7. This model states that when an inflammatory event occurs, such as an 
infection or allergy trigger, the host inflammatory response alters the lung microenvironment, 
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which in turn changes the growth conditions, resulting in dysbiosis of the microbiome 
composition. Some microbial species are favored to grow, and some species cannot continue to 
grow – this changes the microbiome. New species or species that newly become dominant in the 
lung results in a disruption in the homeostasis of the airway microbiome, causing respiratory 
dysbiosis. This respiratory imbalance in turn causes even more inflammation due to the detection 
of PAMPs on new or newly dominant microbial species. This inflammation further changes the 
growth conditions of the lung, creating a positive feedback loop. 
 
Figure 6. The inflammation-dysbiosis cycle 
An inflammatory event occurs, causing many events in the body to occur such as mucus production, catecholamine 
production53, and an increase of vascular permeability and free ATP54, changing growth conditions such as 
temperature, oxygen tension, pH, and nutrient availability. A change in growth conditions creates dysbiosis by 
bacterial clearance and selective growth for certain species of bacteria. More inflammation results from this 
dysbiosis through the immune responses initiated from PAMPs detection of the new bacterial species, causing a 
positive-feedback dysbiosis-inflammation loop. (Information obtained from Dickson, 201441) 
 
 Overall, the lung microbiome remains largely unstudied due to the blurred line between 
the URT and LRT and potential contamination issues. Many researchers are finding ways to 
overcome these obstacles, but not one method has been widely accepted. Inflammation from 
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infection or another inflammatory event changes elimination and immigration factors and alters 
growth conditions of the lung, ultimately creating dysbiosis. This dysbiosis creates an imbalance 
in the homeostatic environment of the lung, thereby creating more inflammation. This 
inflammation further alters growth conditions, further changing the lung microbiome, causing a 
positive feedback loop of inflammation and dysbiosis.  
1.2.4 The Lung Microbiome and M. tuberculosis Infection  
Few studies have been performed investigating TB and the lung microbiome, and results have 
been inconsistent. One of the first TB microbiome studies in 2012 concluded that both healthy 
and Mtb-infected lungs were dominated by Firmicutes and Bacteroidetes and also shared 
Proteobacteria, Actinobacteria28. A second study investigating the differences between Mtb-
infected and healthy lungs found Proteobactera and Bacteroidetes were the dominating 
microbiota in Mtb-infected lungs, while Firmicutes dominated in healthy control lungs55. Botero 
et al. (2014) concluded that Bacteroidetes, Fusobacteria, and Actinobacteria were the 
dominating microbiota in Mtb-infected lungs56. A fourth study found Streptococcus, 
Gramulicatella, and Pseudomonas dominating in Mtb-infected lungs, while healthy lungs had 
dominant populations of Treponema, Catonella, and Coprococcus57. Lastly, a study performed in 
2016 found that the relative abundance of Firmicutes and Actinobacteria was significantly higher 
in TB samples compared healthy controls, where Bacteroides and Proteobacteria were found to 
be higher58. The findings of these studies are summarized in Table 1, which highlight the 
variability between the results of the studies. These studies used sputum samples, which is not 
ideally representative of the lower lung microbiome due to high amounts of contamination from 
the mouth and upper airways. These studies also had relatively small sample sizes, making it 
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harder to find consistencies and trends. Lastly, these studies were cross-sectional, not allowing 
the researchers to assess the changes of the microbiome over time within the same individual. 
Cross-sectional studies make it difficult to investigate how infection impacts the microbiome 
because the microbiome is so variable between individuals.  Since the microbiome varies across 
individuals, cross-sectional studies make it difficult to determine changes induced by infection,  
as this would require extremely large sample sizes. 
A recent study using human BAL samples as their sampling method found Cupriavidus 
to be the dominating genus in Mtb-infected lungs, while Streptococcus was the dominating genus 
found in healthy lungs59. It was mentioned that the generally low quantities of colonizing 
bacteria found in the lung made it difficult to obtain ideal PCR-amplified production of microbial 
DNA. Taken together, the past studies that investigate TB and the lung microbiome are limited 
and inconsistent; this is due to past misinformation about the lung being sterile (causing many 
people to disregard studying the lung microbiome), small sample size, and non-ideal sampling 
methods. 
 
Table 1. Previous lung microbiome and TB studies 
Study Taxa highest in 
Healthy Lungs 













Cheung, 201355 Firmicutes Proteobactera 
Bacteroidetes 
Sputum 




















Overall, the lung microbiome in Mtb infection is largely unstudied. Conclusions obtained 
from past research have been inconsistent. Most past studies were also not ideal in regards to 
sampling method, sample collection timing (cross-sectional vs. longitudinal) and consisted of 
small sample sizes.  
1.3 THE MACAQUE MODEL AND ITS IMPORTANCE IN TUBERCULOSIS AND 
MICROBIOME STUDIES 
1.3.1 The NHP Model and Tuberculosis 
Nonhuman primates (NHPs) are an incredibly valuable model to use in research. NHPs are 
closest to humans genetically compared to other animal models such as mice, Guinea pigs, 
rabbits or zebrafish, resulting in many similarities in immunology, pathogenesis, and 
host/pathogen interactions between NHPs and humans. The macaque model is an ideal animal 
model for both TB studies and microbiome studies.   
Rhesus macaques (Macaca mulatta) and cynomolgus macaques (Macaca fascicularis) 
are two macaque species primarily used in TB studies. Macaques display several similarities to 
humans in regards to Mtb infection; immunology, disease outcome, clinical presentation, 
pathology, and pathogenesis in macaques species are comparable to TB in humans60.   
Previously used scientific animal models, such as the mouse model, are practical and 
relatively inexpensive but aren’t ideal to study the pathogenesis and pathology of Mtb infections. 
In mice, TB granulomas are poorly organized and lack necrosis, unlike in human TB. It is also 
important to note that mice do not display any sort of latent infection; bacterial counts remain 
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high throughout the infection, which progresses until the mouse ultimately dies61. In contrast, 
macaques display a large range of pathology throughout the course of Mtb infection that 
represents the entire clinical spectrum of TB that is seen in humans62. Rhesus macaques, when 
infected with low-dose virulent Mtb, almost always develop active TB. In contrast, when 
cynomolgus macaques are infected, an equal proportion of monkeys will develop active disease 
and latent infection (LTBI)62. The use of the cynomolgus macaque model is a fantastic tool that 
allows researchers to study the entire disease spectrum of Mtb infection, representing human 
disease. 
One of the most important comparisons between the macaque model and humans is the 
similarities in TB granulomas. Granulomas in macaques have a large range of variable 
granuloma heterogeneity. Caseous, suppurative, and non-necrotizing granulomas have been 
found, and some of these granulomas have been mineralized or largely fibrocalicified63. The 
similarities seen in granuloma heterogeneity, organization, and variability between macaque and 
human granulomas allows us to study granulomas and local immune responses more in depth. 
1.3.2 The NHP Model and the Lung Microbiome 
The use of the NHP model in microbiome studies is an excellent opportunity to increase our 
understanding of the lung microbiome composition and how it changes through time. Using a 
research model allows us to collect serial samples throughout the course of Mtb infection, 
allowing us to study the microbiome shifts over time. In humans, it is harder to obtain serial 
sampling of BAL because of the relative invasiveness of the procedure. The use of a NHP model 
also allows us to assess pre- and post-infection changes in the lung microbiome, potentially 
indicating certain bacterial taxa that are important in the course of infection or disease 
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progression. Variables that may alter results, such as diet or environmental conditions, can be 
controlled in an experimental setting unlike in humans that are sampled from the population. 
Inoculum dose and time of infection are also well-controlled. Importantly, the NHP model is 
useful as a bridge to human studies because it has been shown that the composition of the NHP 
gut microbiome is more similar to humans than other animal models64. Like humans, NHPs are 
also outbred65, creating a diverse population variability that is similar to human variability. The 
use of macaques as an in vivo model is ideal for studying the changes of the lung microbiome in 
regards to Mtb infection. 
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2.0  STATEMENT OF INTENT, HYPOTHESIS, AND SPECIFIC AIMS 
A longitudinal study investigating the changes of the lung microbiome before, during, and after 
Mtb infection has not been reported. For our study, the main goal was to assess whether Mtb 
infection induces a significant change in the lung microbiome in macaques. We hypothesized 
that inflammation from Mtb infection influences the variability of the lung microbiome in 
macaques. These changes and disruptions in the lung microbiome may have implications for 
overall lung health and also may play a role in the outcome of Mtb infection. We first determined 
the identity and compared community clusters of the lung and oral cavity in macaques to 
investigate how the oral cavity influences the lung. Second, we investigated the community 
structure and stability of the lung microbiome throughout the course of Mtb infection in 
macaques, allowing us to see how the lung microbiome changes throughout the course of 
infection. Lastly, we investigated whether the microbiota variability in the lung was associated 
with inflammation. BAL samples collected from macaques at different time points before and 
after infection were sequenced. The composition, diversity, and variability of the lung 
microbiome throughout the course of infection was determined. With this information, we 
investigated whether variability of the lung microbiome correlated with the variability of 
inflammation throughout infection, indicating that the inflammation due to Mtb infection 
changes the lung microbiome in macaques. This project is a collaboration with the Ghedin Lab 
(NYU), who performed the 16S sequencing and some statistical analyses. 
 22 
 
2.1 SPECIFIC AIM 1: IDENTIFY AND COMPARE COMMUNITY CLUSTERS OF 
THE LUNG AND ORAL CAVITY IN MACAQUES. 
One of the main questions in lung microbiome studies is how much the microbiota of the oral 
cavity (the URT) influences that of the lung. Using a cynomolgus macaque model, we obtained 
both oral and BAL samples to be sequenced to identify the composition of each respective 
environment. 16S rRNA sequencing helped generate OTUs which made comparing the relative 
abundance and composition of the oral cavity and lung microbiota. Alpha-diversity was 
determined between the two sampling sites, and a principle coordinate analysis was performed to 
further distinguish the differences between the oral and lung spaces. This aim will provide crucial 
data of the similarities and differences between the oral cavity (and URT) and the LRT. We 
hypothesized that there will be a difference in community structure between the oral cavity and 
lung. 
2.2 SPECIFIC AIM 2: INVESTIGATE THE COMMUNITY STRUCTURE AND 
STABILITY OF THE LUNG MICROBIOME THROUGHOUT THE COURSE OF M. 
TUBERCULOSIS INFECTION IN MACAQUES. 
How the lung microbiome changes throughout the course of Mtb remains largely unstudied. BAL 
samples were obtained from time points from before and after Mtb infection to study the changes 
throughout infection. Obtaining samples before infection and 1, 4, and 5 months post-infection 
made it possible to study the changes in the OTU composition and relative abundance change in 
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the microbiota present in the lung throughout infection. We hypothesize that there will be a change 
in the overall stability and composition of the lung microbiome after Mtb infection. 
2.3 SPECIFIC AIM 3: ASSOCIATE MICROBIOTA VARIABILITY IN THE LUNG 
WITH INFLAMMATION. 
Inflammation plays a large role in Mtb infection and is important in the immunology of the 
granuloma. We evaluated how levels of inflammation vary over time in individual macaques using 
PET/CT imaging. By quantifying overall FDG avidity, we have a measure of total inflammation, 
referred to as ‘total PET HOT’. We then investigated whether there is an association between the 
variability of the lung microbiome and the changes of inflammation throughout Mtb infection by 
assessing the correlations between total PET HOT, relative abundance, and alpha-diversity over 
time. If there is a correlation between microbiome variability and PET HOT, we will investigate 




3.0  METHODS 
3.1 INFECTION AND NHP MODEL 
Twenty-six cynomolgus macaques (Macaca fascicularis) were used for this study. Macaques 
were obtained from Valley Biosystems (Sacramento, CA) and housed in designated biosafety 
level 3 (BSL-3) laboratory animal space at the University of Pittsburgh. All macaques receive 
essentially the same diet, including enrichment foods, and are housed in the same facility. 
Monkeys used for this study were parts of separately funded studies. We often perform serial 
BALs as a normal procedure throughout infection. The BAL collection procedure for the 
microbiome studies were performed slightly different than usual BAL collection procedures, 
explained below. These monkeys remain un-manipulated other than Mtb infection during the 
period of microbiome sampling. 
Macaques were infected with <25 CFU Mtb strain Erdman via bronchoscopic instillation 
into the lower lung, as previously described in 66 and 67. PET/CT imaging was used post-
infection to determine which lobe was successfully infected, as well as subsequent lobe 
involvement due to dissemination of the infection. 
3.2 BRONCHOALVEOLAR LAVAGE COLLECTION 
Oral, saline/bronchoscope control wash, and right and left lower lobe samples were collected 
approximately 3 weeks pre-infection and approximately 1, 4, and 5 months post-infection. Oral 
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washes were obtained by a 5mL rinse of a cheek pouch. Bronchoscope washes were obtained by 
a 5mL saline wash of the sterilized instrument. The monkeys’ mouths were swabbed with 
antiseptic chlorohexane immediately prior to the insertion of the bronchoscope for BAL 
collection, minimizing contamination from the oral cavity. A 7mL lavage of the left lower lobe is 
performed, followed by sterilization of the bronchoscope via antiseptic solution (Cidvex, Civco 
Medical Solutions) and lavage of the right lower lobe is performed thereafter. Lavages yield 
approximately 4-5 mL from each lobe. After collection lavages were immediately aliquoted into 
4.5 mL cryovials and frozen at -80°C until time of DNA extraction. Overall, each macaque will 
have 4 samples at each time point (oral wash, saline bronchoscope wash, right lower lung, and 
left lower lung), ultimately yielding 372 total samples. For this study, data from the first 10 
monkeys were analyzed. An additional data set from 16 more monkeys is awaiting sequencing 
and analysis. 
3.3 DNA EXTRACTION/ISOLATION 
DNA extraction was performed on all collected samples. Previously collected samples were 
removed from -80°C, thawed, and centrifuged. The PowerSoil® DNA Isolation Kit (MO BIO) 
was used in which BAL samples (containing liquid and cells) were thoroughly homogenized and 
lysed, then bound to a silica membrane in order to capture DNA for DNA elution. This kit 
incorporated the use of bead-beating tubes to ensure thorough homogenization and cell lysis. 
Extraction was performed in BSL-3 laboratory conditions under a biological safety 
cabinet using sterile technique. Reagent controls and PBS controls were performed for each 
monkey to assess any residual DNA from kit reagents, tubes, and pipette tips. Proper PPE was 
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worn at all times, and BSL-3 protocols were followed. Measures were taken to minimize 
contamination, such as using ultra-violet light and bleach to sterilize the working space and 
equipment before extraction, changing gloves after every centrifugation step, only extracting 
DNA from one macaque at a time to minimize cross-contamination between monkeys, using a 
microcentrifuge specific to DNA extractions that is kept under a biosafety cabinet at all times, 
and using designated pipettes and sterile tips. 
3.4 16S RRNA SEQUENCING AND DATA ANALYSIS 
Sample preparation for 16S rRNA sequencing and sequencing of DNA eluted from BAL 
samples was performed by Dr. Elodie Ghedin and lab members (NYU). Barcodes were added to 
DNA to prime the target V4 hypervariable amplicon. Amplicons were purified and library 
preparation was performed using the KAPA HTP Library Preparation Kit (KAPA Biosystems). 
Primer dimers were removed and confirmation of removal was given by TapeStation (Agilent 
Genomics). Library quantification was performed using the KAPA Library Quantification Kit 
(KAPA Biosystems), which contain DNA standards, 10X Primer Premix, and KARA SYBR® 
FAST qPCR Kits, to quantify the number of amplifiable molecules in the prepared Illumina 
library.  
After qPCR was performed, the V4 region was sequenced using the MiSeq (Illumina) 
instrument. The Mothur pipeline, modified for the MiSeq platform, includes the removal of low 
quality reads, chimeras (UCHIME), non-mate-paired reads, and merging of paired-end reads. 
Classification of sequences to the genus level was made by using the RDP (Ribosomal Database 
Project) classifier. Operational Taxonomic Units (OTUs) were generated by clustering sequences 
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that share >97% nucleotide identity similarities (UCLUST). The ‘top 10 OTUs’ were generated 
by choosing the OTUs that had the highest proportion of reads present in the BAL samples. 
Using the taxonomic assignments and OTU-based profiles generated from sequencing data, 
many ordination, clustering, and community structure analyses were performed. Abundance and 
ubiquity between samples were visualized using CORBATA and QIIME. 
3.5 PET/CT IMAGING 
PET/CT scans were obtained from macaques at different time points post-infection, as described 
in 24 and 25. 18F-fluorodeoxyglucose (FDG) was used as a probe to label metabolically active 
cells, serving as a nonspecific marker of inflammation. FDG avidity can give us total PET HOT, 
allowing us to obtain a quantifiable measure of inflammation over time. FDG avidity is 
normalized to each macaque’s dorsal muscle, individually, allowing us to normalize baseline 
inflammation. 
3.6 STATISTICAL ANALYSIS 
Statistical analysis in regards to the lung microbiome portion of the study was performed by Dr. 
Elodie Ghedin and lab members (NYU). Analyses were performed on an integrated QIIME and 
R package. Whole community structure changes were analyzed via Adonis. PCoA plot was 
generated by Yixuan Ma, Ghedin Lab, and used with permission. 
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Statistical analyses were performed at the University of Pittsburgh using JMP Pro 11 and 
Graphpad Prism 6, with the help of Pauline Maiello. Wilcoxon rank sum analyses were 
performed to determine differences of individual OTUs between involved and uninvolved lobes, 
differences over time, and differences between the oral cavity and lower lobe samples. Individual 
OTU relative abundance correlations (at four months post-infection) were performed using a 
Spearman’s 𝞀𝞀 Correlation, as were correlations between the ranges of OTU relative abundances 
and range of total PET HOT. Spearman’s 𝞀𝞀 and Pearson’s r were used for analyzing the 
correlation between alpha-diversity and total PET HOT over time and range of diversity and 
range of total PET HOT of involved lobes, respectively. An unpaired t-test was performed to 
compare the range of diversity over time between involved and uninvolved lobes. Diversity was 




4.0  RESULTS 
4.1 EXPERIMENTAL OVERVIEW 
To investigate the changes in microbiome variability throughout the course of Mtb infection, 
samples were collected at multiple time points (Fig. 7, top) from macaques. Oral cavity swab 
samples were collected to assess differences in microbial diversity (species richness and 
evenness) between the oral cavity and lung samples. A bronchoscope saline wash was performed 
to control for any residual DNA on the bronchoscope during sample collections (Fig. 7, bottom). 
PET/CT imaging was also performed 1, 4, and 5 months post-infection. 
 
Figure 7. Experimental layout of sample collection sites and timeline 
Oral wash, right lower lobe (RLL), left lower lobe (LLL), and saline bronchoscope wash samples were collected 




Two cohorts of 10 and 16 macaques were used in this study yielding a total of 424 samples, 
including reagent and PBS controls during DNA extraction (Table 2).  
 
Table 2. Sample distribution of cohorts 











1 10 70 36 36 20 162 
2 16 114 58 58 32 262 
 
4.2 THE ORAL CAVITY AND LUNG COMMUNITY STRUCTURES ARE 
DISTINCT 
To determine how the community structures between the oral cavity and the lung differ, 16S 
rRNA sequencing was performed on oral cavity swab samples and bronchoalveolar lavage 
(BAL) samples. Sequencing was performed by the Ghedin Lab, NYU and the resulting data was 
used with permission. Lobe involvement is determined by inflammation: lobes that displayed 
inflammation via PET/CT imaging were grouped as ‘involved lobes’, and lobes that displayed no 
inflammation via PET/CT imaging were grouped as ‘uninvolved lobes’. It is important to note 
that absence of inflammation does not necessarily mean absence of infection; it is possible to 
have granulomas that are not FDG avid in a lobe, and therefore minimal inflammation. The 
following presented data are for the first cohort of N=10 macaques. The second cohort of N=16 
macaques are being sequenced and analyzed. Thus, the following data is preliminary.  
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The genetic diversity between oral and lung BAL samples was visualized through the use 
of a principle coordinate analysis (Fig. 8). The data shows that oral samples cluster tightly 
together in one space, away from BAL samples, while the BAL samples cluster together in a 
different space. There is no pronounced difference in clustering between involved and 
uninvolved lobes. This data suggests that the genetic diversity of the oral cavity microbiome and 
the lung microbiome are distinct from one another, suggesting that the lung microbiome is not 
strictly just contamination by the oral cavity when the BAL washes were performed. 
 
Figure 8. Principle coordinate analysis comparing the genetic diversity between oral wash and lung BAL samples 
 
Oral wash samples (orange) cluster together, while lung BAL samples (pink and blue) cluster together in a different 




Operational taxonomic units (OTUs) were generated by UCLUST, clustering together 
sequences that shared >97% nucleotide identity similarities. Our ‘top 10 OTUs’ were generated: 
Burkholderia (genus-level), Actinomycetales (order-level), Actinobacillus (genus-level), 
Neisseria (genus-level), Aggregatibacter (genus-level), Moraxellaceae (family-level), 
Fusobacterium (genus-level), Acinetobacter (genus-level), Gemellaceae (family-level), and 
Streptococcus (genus-level). These OTUs had the highest proportion of reads present in the BAL 
and oral wash samples after sequencing (data not shown). To assess whether there was a 
compositional difference between the oral wash samples and lobe samples in regards to the top 
10 OTUs, the relative abundances of the top 10 OTUs were determined for the oral wash, 
involved lobe, and uninvolved lobe samples (Fig. 9). Relative abundance is relative to all OTUs 
found in the sample. Four of the top 10 OTUs were found in noticeably higher proportions in 
lobe samples vs. oral samples (Burkholderia, Actinomycetales, Moraxellaceae, and 
Acinetobacter), showing that a compositional difference between oral wash samples and lower 
lobe does exist. This further confirms our observation that the lung microbiome has a distinct 




Figure 9. Relative abundance of top 10 generated OTUs between oral wash, involved lobe, and uninvolved lobe 
samples 
 
Relative abundance is relative to all OTUs found in the sample. 
 
To determine how lung and oral microbiome species diversity changes over time, the 
community alpha-diversity was determined by using the average Inverse Simpson Index for 
saline bronchoscope wash, oral wash, involved lobe, and uninvolved lobe samples at each time 
point (Fig. 10). A high Inverse Simpson Index confers a higher level of alpha-diversity. Oral 
wash, involved lobes, and uninvolved lobes were compared to one another to determine any 
trends of alpha-diversity. Our results show that the oral microbiome maintains a high amount of 
alpha-diversity pre-Mtb infection and throughout the entire course of infection. The oral wash 
 34 
 
had a significantly higher level of alpha-diversity compared to all lung samples (p=0.0001, 
Wilcoxon rank sums). 
The stable, high level of alpha-diversity of the oral cavity contrasts with the lobe samples, 
which have more variability in alpha-diversity over time. Alpha-diversity is variable in lobe 
samples throughout the course of Mtb infection, increasing and decreasing at different time 
points. There is a trend towards more species diversity in the involved vs. the uninvolved lobes 4 
months post-infection (p=0.0574, Wilcoxon rank sums). Our results also show that the saline 
bronchoscope control wash maintains a low level of alpha-diversity before and throughout 
infection, implying that there is minimal contamination from the upper respiratory tract when 
collecting BAL samples. It is important to reiterate that these data represent only the first cohort 





Figure 10. Lung microbiome diversity over the course of Mtb infection. 
 
Alpha-diversity of involved lobes (pink) were calculated for each time point. The same was performed with 
uninvolved lobes (blue), oral washes (orange) and saline bronchoscope control washes (purple). 
 
Overall, these data show that the community structures of the oral cavity and the lung are 
distinct, confirming that the lung cavity is not just a contamination by the oral flora. 
4.3 LUNG MICROBIOTA ARE VARIABLE THROUGHOUT INFECTION 
Next, our goal was to determine how the composition of the lung microbiome changes throughout 
the course of Mtb infection. The relative abundance of the top 10 OTUs in BAL samples of 
involved lobes was determined for each time point for each individual monkey over time (Fig. 11). 
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Our data show that the relative abundances of the top 10 OTUs over time is variable. It is also 
apparent that the relative abundances and overall composition of the top 10 OTUs stays relatively 
stable over time. For example, monkey #15313 displays similar relative abundances of the top 10 
OTUs throughout baseline and infection. In contrast, some monkeys display a high amount of 
variability in the relative abundances and composition of the top 10 OTUs over time. Monkey 
#16914 displays a wide range of changes in the relative abundances of the OTUs over time. For 
example, at baseline a high relative abundance of Moraxellaceae is seen, but as infection 
progresses, the relative abundance of this OTU decreases as Burkholderia becomes a dominating 
OTU by month 5. Overall, some macaques display high microbiota variability and some display 
low amounts of microbiota variability. 
 
  




Some monkeys display low amounts of change in the composition of these OTUs over time, while others display 
high amounts of change. (B = Pre-infection; 1, 4, 5 = 1, 4, 5 months post-infection, respectively). Relative 
abundance is relative to all OTUs found in the sample. 
 
 
We investigated how individual OTU relative abundance changes over time between 
uninvolved and involved lobes. Figure 12 shows uninvolved lobes and involved lobes change 
differently in terms of relative abundance of OTUs over time. For example, the relative 
abundance of certain OTUs in the involved lobe, such as Acinetobacter, stay relatively stable 
until 4 months post-infection, followed by a sharp increase. In contrast, the relative abundance of 
Acinetobacter in the uninvolved lobes increase throughout infection, and sharply decline after 4 
months post-Mtb infection. 
 




We wanted to investigate if there were any differences of OTU relative abundance 
between involved and uninvolved lobes before and after Mtb infection. Our analyses show that 
before infection, there are no significant differences in relative abundance of the top ten OTUs 
between involved and uninvolved lobes (Table 3). However, after infection there are significant 
differences in relative abundance of between involved and uninvolved lobes for specific OTUs. 
Our results show that post-Mtb infection, Fusobacterium and Aggregatibacter is significantly 
more relatively abundant in involved lobes, while Burkholderia is significantly more relatively 
abundant in uninvolved lobes (Table 3, Figure 13). Taken together, these data show relative 
abundance of specific OTUs change post infection, and certain OTUs are more relatively 
abundant in either involved or uninvolved lobes post-Mtb infection, suggesting that Mtb 
infection changes the lung microbiome.  
 
Table 3. Involved vs uninvolved lobes, OTU relative abundance p-values  
OTU pre-Mtb p-value post-Mtb p-value 
Actinomycetales 0.5208 0.2333 
Streptococcus 0.7345 0.8522 
Gemellaceae 0.8506 0.0697 
Fusobacterium 0.7345 0.0396 
Burkholderia 0.2703 0.0481 
Neisseria 1 0.2412 
Actinobacillus 0.7345 0.2659 
Aggregatibacter 0.5208 0.0437 
Moraxellaceae 0.8506 0.9765 





Figure 13. OTU relative abundance pre- vs. post-Mtb infection of involved and uninvolved lobes 
 
Median relative abundance is plotted for pre-infection (0) and post-infection (1). 
  
 
To further investigate at what time point these post-infection differences between 
involved and uninvolved lobes were the greatest, how OTU relative abundance changes over 
time was assessed for each time point (Fig. 14). Our analyses show that there is the greatest 
difference between OTU relative abundance at four months. At four months, involved lobes had 
significantly higher relative abundances of Fusobacterium (p=0.0473) and Aggregatibacter 
(p=0.0387). In contrast, uninvolved lobes had a significantly higher relative abundance of 
Burkholderia (p=0.0201). It is important to note that visually, it looks like there is a higher 
difference in the uninvolved vs. involved lobes at 5 months post-infection for Burkholderia than 
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at 4 months post-infection. However, there was a lack of 5 month samples (due to treatment or 
necropsy), reducing the sample size at this time point and ultimately making statistics on this 
time point difficult. The addition of the second cohort of macaques will improve our sample size, 
allowing us to fully analyze the differences between uninvolved and involved lobes. 
 
Figure 14. OTU relative abundance (median) over time by involvement 
 
An even deeper investigation of these OTUs show that the relative abundance of OTUs 
are not only variable over time, but it is also variable among monkeys. Figure 15 shows 
examples of relative abundances of OTUs over time by individual monkey. The amount of 
relative abundance per OTU changes throughout time and changes differently in each macaque, 









Next, we assessed how alpha-diversity changes over time. A trend (p= 0.0574) of an 
increased alpha-diversity existed in involved lung lobes at 4 months post-infection (Fig. 16), 




Figure 16. Alpha-diversity (median) over time by involvement 
 
We also evaluated how alpha-diversity changes over time in individual monkeys in 
involved lobes (Fig. 17). Our data show, that much like relative abundance, diversity is also 
variable within monkeys and among monkeys throughout time. 
 




Spearman 𝞀𝞀 correlation analyses were performed to test whether there was any 
correlation between the relative abundances of the top 10 OTUs. We found there were both 
positive and negative correlations (Fig. 18A-C) with specific OTUs at 4 months post-infection in 
involved lobes. Gemellaceae was significantly positively correlated with Aggregatibacter and 
Actinobacillus, showing that when Gemellaceae is highly abundant, Aggregatibacter and 
Actinobacillus are likely to be highly abundant as well (Fig. 18A-B). In contrast, Neisseria was 
significantly negatively correlated with Actinomycetales, showing that when Neisseria is highly 
abundant, Actinomycetales is found in lower levels of relative abundance (Fig. 18C).  
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Figure 18. Spearman 𝞀𝞀 correlations between individual OTUs for all lobes 
A) Gemellaceae vs. Aggregatibacter; B) Gemellaceae vs. Actinobacillus; C) Neisseria vs. Actinomycetales show 
significant (p < 0.05) correlations. 
 
Taken together, these data show that the change of the lung microbiota is variable 
throughout time in regards to both OTU relative abundance and alpha-diversity. This variability 
is seen within individual macaques over time and among different macaques. Certain bacterial 
OTUs are characteristic of either involved lobes or uninvolved lobes. Lastly, individual OTUs 
are correlated with each other at 4 months post-Mtb infection. 
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4.4 INFLAMMATION IS VARIABLE THROUGHOUT INFECTION 
To assess the variability of inflammation throughout the course of Mtb infection, total PET HOT 
was determined by quantifying FDG avidity, a nonspecific marker of inflammation (Fig. 19). 
The FDG probe labels metabolically active cells, inferring inflammation is occurring during Mtb 
infection. Our data shows us that total PET HOT changes throughout the course of infection 
within individual monkeys. An individual macaque at 1 month post-infection can have a 
relatively low total PET HOT, but by month 4 their total PET HOT may increase to a higher 
level. By month five, most macaques’ total PET HOT levels seems to start to decline. This 
implies that the amount of inflammation throughout the course of Mtb is variable within 
individual monkeys. Inflammation is also variable between monkeys. Some monkeys maintain a 
relatively high amount of inflammation (ex. #16814), while other monkeys maintain a relatively 





Figure 19. Total PET HOT over the course of Mtb infection for N=26 macaques 
 
Each line on the graph represents a different macaque. The amount of inflammation changes throughout infection in 
individual macaques and is variable between macaques. 
 
We have shown that relative abundance, alpha-diversity, and total PET HOT are variable 
within and among macaques over the course of infection. To determine whether the variability of 
total PET HOT over the course of Mtb infection correlates with the variability of the microbiota 
over time, we investigated total PET HOT in regards to both relative abundance of specific 
OTUs and alpha diversity. Sample size for these analyses were limited to the first cohort of 
macaques. The following data is preliminary. 
A Spearman’s 𝞀𝞀 correlation analysis was performed on the ranges of total PET HOT and 
ranges of relative abundance of the top ten OTUs. Using the range gave us the overall degree of 
change. No significant correlations were observed (Table 4), implying that high changes in 
relative abundance are not correlated with changes in total PET HOT at this time. 
 




Table 4. Spearman’s 𝞀𝞀 correlation values and associated p-values in involved lobes 
Variable 1 vs. Variable 2 Spearman's 𝞀𝞀 (p-value) 
Range (PET HOT) Range (Actinomycetales) 0.7162 
Range (PET HOT) Range (Streptococcus) 0.6033 
Range (PET HOT) Range (Gemellaceae) 0.3273 
Range (PET HOT) Range (Fusobacterium) 0.9038 
Range (PET HOT) Range (Burkholderia) 0.6111 
Range (PET HOT) Range (Neisseria) 0.9562 
Range (PET HOT) Range (Actinobacillus) 0.7245 
Range (PET HOT) Range (Aggregatibacter) 0.8174 
Range (PET HOT) Range (Moraxellaceae) 0.5051 
Range (PET HOT) Range (Acinetobacter) 0.2082 
 
 
 We then investigated the relationship between alpha-diversity and total PET HOT, 
allowing us to see whether there were any correlations between the richness and evenness of the 
lung microbiome and inflammation. A Spearman’s 𝞀𝞀 correlation between total PET HOT and 
Inverse Simpson Index of involved lobes revealed that alpha-diversity is not associated with 
inflammation in involved lobes (p=0.4858) within the first cohort of macaques. Our results also 
show that at this time, changes in total PET HOT are not associated with changes in alpha-
diversity over time (p=0.9436).  
 Lastly, we wanted to know whether a high range in alpha diversity over time could be a 
predictor of lobe involvement (Fig. 20). Our data show that there is no significant difference 




Figure 20. Range of diversity over time in uninvolved and involved lung lobes 
 
A significant difference between uninvolved and involved lobes does not exist (p = 0.5404, unpaired t-test). 
 
 
 Taken together, our preliminary results suggest that although PET HOT is variable 
throughout infection, it is not associated with relative abundance of our top ten OTUs or alpha-
diversity. At this time, the range of diversity cannot be used to predict lung inflammation 
involvement. However, this sample size is very limited, and results may improve when the 
second cohort of macaques are added to the dataset. 
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5.0  DISCUSSION 
We assessed how the lung microbiome of macaques change throughout the course of Mtb 
infection, and how the composition of the lung microbiome differs from that of the oral cavity. 
There is a compositional difference between oral wash samples and BAL samples in regards to 
overall genetic diversity and OTU relative abundance. There is a trend of increased average 
alpha-diversity within involved lobe sides compared to uninvolved lobes at 4 months post-Mtb 
infection. The overall relative abundances for the ‘top ten’ OTUs are highly variable throughout 
infection in some monkeys but stay relatively stable in other monkeys. OTU relative abundance 
and alpha-diversity of involved lobes is variable over the course of Mtb infection within 
macaques and among macaques. It is also shown that certain bacterial taxa are correlated with 
each other - Gemellaceae was significantly positively correlated with Aggregatibacter and 
Actinobacillus. We also investigated how inflammation changes over time due to Mtb infection 
in macaques. Our data show that inflammation over time is variable within individual monkeys 
and also among macaques. Lastly, we investigated how the changes in the microbiota are 
associated with inflammation. Our results show that at this time, there is no correlation between 
PET HOT and relative abundance or alpha-diversity. However, this may change once the second 
cohort of monkeys is added to the dataset. 
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5.1 POSSIBLE MECHANISM 
Inflammation variability throughout infection and among different macaques is perhaps caused by 
the vast heterogeneity of Mtb infection in general. Disease is not the same within each macaque, 
and each macaque does not progress throughout infection the same way. Differences in immune 
responses, granuloma dynamism and heterogeneity, and other factors may play a role in 
inflammation variability.  
The changes of the microbiota abundance and diversity throughout infection may be related 
to infection, but this remains unclear. Even if microbiota variability is not directly related to 
inflammation, disease parameters such as CFU, disease spread, and gross pathology score may 
still be correlated to these changes in the microbiome of the lung. Newly introduced species into 
the lung post-infection may be a result from increased microaspiration or an increase in other 
immigration factors, causing an influx of members to travel from the oropharynx down intro the 
lower airway. Correlations between OTUs may be a result of changes in growth conditions in the 
lung, or due to microbial interactions between species. 
It is interesting to note that multiple ‘peak’ events were observed at 4 months post-Mtb 
infection: peak total PET HOT and largest difference of OTU relative abundance and alpha-
diversity between involved and uninvolved lobes. This time point also correlates with the peak of 
Mtb infection. A more thorough investigation of events happening during this time point will be 
performed. Unfortunately, many questions regarding microbiota variability throughout the 
course of Mtb infection remain unanswered. We suspect that further investigation and analyses 




Lung microbiome studies present a number of obstacles regarding sample contamination and 
bacterial yield. We believe we minimized contamination to the best of our ability (see Methods), 
and samples were qPCR amplified before sequencing to get a better picture of the relative 
abundance found in the macaque BAL. Because of high variability in in vivo studies, each 
macaque was assessed individually when seeing how the relative abundance of the ‘top ten’ 
OTUs changed over time. The use of the cynomolgus macaque was an ideal model for both Mtb 
infection and lung microbiome assessment. These NHPs present the full spectrum of disease and 
allowed us to longitudinally sample BAL throughout infection. 
 Using an NHP model allows us to control many possible confounding variables. 
However, we do not have control over any antibiotic usage or treatments given to the macaques 
before they become enrolled in our studies. If macaques were treated with antibiotics before 
enrollment, this may alter the baseline lung microbiome. When the macaques are brought into 
the university, quarantine procedures involve standard protocol antibiotic treatments. For 
example, macaques may get treated for potential parasitic worms (with ivermectin). Nonetheless, 
we try to limit antibiotic usage, and record any treatments given to the macaques prior to 
enrollment, allowing us to take note of this when looking at the microbiota pre-Mtb infection. 
Looking at our data, it is important to note that sample size remains an issue for this 
cohort. For this first cohort, there are few total PET HOT data for early (1 month) time points. In 
contrast, the diversity/abundance data is mainly at early time points. Not all macaques were 
sampled to 5 months post-infection due to treatment or necropsy, and not all PET/CT scans were 
obtained at 1 month post-Mtb infection, leaving many gaps within the datasets (Fig. 21). This 
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greatly reduced our ideal sample size when assessing correlations between total PET HOT and 
relative abundance or alpha-diversity over time. 
 
Figure 21. Alpha-diversity and total PET HOT over time by individual macaque 
 
However, the second cohort of macaques contains a fuller data set, improving our data 
overlap and sample size. This will allow us to fully assess if there is a correlation between 
inflammation and the changes in the lung microbiome over time. 
5.3 FUTURE DIRECTIONS 
In the future, we will investigate what may account for some macaques to display a high amount 
of variability of the relative abundance of the ‘top ten’ OTUs throughout infection and other 
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macaques stay relatively stable throughout time. All correlation analyses will be rerun once the 
second cohort of macaques are added to the data, allowing us to improve our sample size.  
 It is important to note that we did not find Mtb in our BAL samples. This may be for a 
number of reasons: Mtb likely clusters together in an OTU (Actinomycetales), it is possible that a 
different region of the 16S rRNA is used to distinguish Mtb from other species, or other taxa 
have outcompeted Mtb resulting in a very low relative abundance. We will evaluate this 
predicament further upon deeper analysis. 
Because of the novelty of this type of study, we only assessed early time points of 
infection (until 5 months post-Mtb infection). This is because after this time point, macaques are 
usually treated or necropsied. This makes it difficult to assess the full spectrum of changes of the 
microbiome that can occur throughout infection. However, future studies will investigate the 
effects of both treatment and/or SIV infection on the lung microbiome. We also will be assessing 
the microbiome and metatranscriptome of individual granulomas. 
5.4 PUBLIC HEALTH SIGNIFICANCE AND FINAL THOUGHTS 
Overall, the changes in inflammation, microbiome relative, and abundance and diversity 
throughout the course of Mtb infection are variable. This variability is seen throughout time 
within individual monkeys and also seen among different monkeys. Our data has shown that 
there is no association between total PET hot and relative abundance of certain OTUs or alpha-
diversity. However, with the addition of the second cohort of monkeys and increase of sample 
size, trends may emerge that could not have been assessed before. These results are important to 
the field of TB and public health importance because it may have implications for overall lung 
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health or disease outcome. If associations are found between inflammation and the lung 
microbiome, alterations to the lung microbiota could serve as a form of treatment to reduce 
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